Cargando…
Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria
INTRODUCTION: To generalize safety and efficacy findings, it is essential that diverse populations are well represented in Alzheimer's disease (AD) drug trials. In this review, we aimed to investigate participant diversity in disease‐modifying AD trials over time, and the frequencies of partici...
Autores principales: | Franzen, Sanne, Smith, Jade Emily, van den Berg, Esther, Rivera Mindt, Monica, van Bruchem‐Visser, Rozemarijn L., Abner, Erin L., Schneider, Lon S., Prins, Niels D., Babulal, Ganesh M., Papma, Janne M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964823/ https://www.ncbi.nlm.nih.gov/pubmed/34590409 http://dx.doi.org/10.1002/alz.12433 |
Ejemplares similares
-
The recognition and management of neuropsychiatric symptoms in early Alzheimer's disease: a qualitative study among Dutch memory clinic physicians
por: Eikelboom, Willem S., et al.
Publicado: (2022) -
Cross-cultural neuropsychological assessment in the European Union: a Delphi expert study
por: Franzen, Sanne, et al.
Publicado: (2020) -
The Multidimensional Prognostic Index Predicts Mortality in Older Outpatients with Cognitive Decline
por: Overbeek, Femke C. M. S., et al.
Publicado: (2022) -
Ethics of rooming-in with COVID-19 patients: Mitigating loneliness at the end of life
por: Bunnik, Eline M., et al.
Publicado: (2022) -
Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials
por: van Eijk, Ruben P.A., et al.
Publicado: (2019)